KR20240156633A - 항-cd39 항체 및 이의 용도 - Google Patents

항-cd39 항체 및 이의 용도 Download PDF

Info

Publication number
KR20240156633A
KR20240156633A KR1020247032745A KR20247032745A KR20240156633A KR 20240156633 A KR20240156633 A KR 20240156633A KR 1020247032745 A KR1020247032745 A KR 1020247032745A KR 20247032745 A KR20247032745 A KR 20247032745A KR 20240156633 A KR20240156633 A KR 20240156633A
Authority
KR
South Korea
Prior art keywords
seq
antibody
amino acid
acid sequence
heavy chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247032745A
Other languages
English (en)
Korean (ko)
Inventor
크리스틴 엘리자베스 바우먼
아다 페이 시안 첸
에스테르 페르난데즈-살라스
나이젤 펠럼 클린턴 워커
샤오닝 자오
야오화 후
시웨이 니에
지지에 구
Original Assignee
아르커스 바이오사이언시즈 인코포레이티드
우시 바이올로직스 아일랜드 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2022/079021 external-priority patent/WO2023164872A1/en
Application filed by 아르커스 바이오사이언시즈 인코포레이티드, 우시 바이올로직스 아일랜드 리미티드 filed Critical 아르커스 바이오사이언시즈 인코포레이티드
Publication of KR20240156633A publication Critical patent/KR20240156633A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020247032745A 2022-03-03 2023-03-02 항-cd39 항체 및 이의 용도 Pending KR20240156633A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
PCT/CN2022/079021 WO2023164872A1 (en) 2022-03-03 2022-03-03 Anti-cd39 antibodies and use thereof
CNPCT/CN2022/079021 2022-03-03
CN2022126070 2022-10-19
CNPCT/CN2022/126070 2022-10-19
PCT/CN2023/079295 WO2023165561A1 (en) 2022-03-03 2023-03-02 Anti-cd39 antibodies and use thereof

Publications (1)

Publication Number Publication Date
KR20240156633A true KR20240156633A (ko) 2024-10-30

Family

ID=87883061

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247032745A Pending KR20240156633A (ko) 2022-03-03 2023-03-02 항-cd39 항체 및 이의 용도

Country Status (13)

Country Link
US (2) US11970543B2 (https=)
EP (1) EP4486785A1 (https=)
JP (2) JP7712496B2 (https=)
KR (1) KR20240156633A (https=)
CN (2) CN119173535A (https=)
AR (1) AR128688A1 (https=)
AU (1) AU2023227964A1 (https=)
CA (1) CA3253669A1 (https=)
CL (1) CL2024002620A1 (https=)
IL (1) IL315351A (https=)
MX (1) MX2024010646A (https=)
TW (1) TW202340243A (https=)
WO (1) WO2023165561A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025539459A (ja) * 2022-12-01 2025-12-05 イナート・ファルマ・ソシエテ・アノニム 癌におけるネオアジュバント処置のための組成物および方法
CN119798442B (zh) * 2023-12-27 2025-12-16 华润生物医药有限公司 特异性结合cd39的纳米抗体及其用途
WO2026006759A1 (en) 2024-06-28 2026-01-02 Arcus Biosciences, Inc. Pharmaceutical compositions, dosage forms, and methods of making and using same

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2238170B1 (en) * 2008-01-31 2016-11-23 INSERM - Institut National de la Santé et de la Recherche Médicale Antibodies against human cd39 and use thereof for inhibiting t regulatory cells activity
EP2654789B1 (en) 2010-12-22 2018-05-30 Orega Biotech Antibodies against human cd39 and use thereof
EP3215538A4 (en) * 2014-11-07 2018-07-04 Igenica Biotherapeutics, Inc. Anti-cd39 antibodies and uses thereof
CA3005986A1 (en) 2015-11-23 2017-06-01 Innate Pharma Cd39 vascular isoform targeting agents
EP3912681A1 (en) 2016-03-14 2021-11-24 Orega Biotech Anti-cd39 antibodies
EP3744348B1 (en) 2016-05-06 2022-03-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Pharmaceutical compositions for the treatment of chemoresistant acute myeloid leukemia (aml)
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
IL269150B2 (en) 2017-03-16 2025-04-01 Innate Pharma Cancer treatment preparations and methods
MY202018A (en) * 2017-07-31 2024-03-29 Trishula Therapeutics Inc Anti-cd39 antibodies, compositions comprising anti-cd39 antibodies and methods of using anti-cd39 antibodies
BR112020006809A2 (pt) 2017-10-06 2020-10-06 Innate Pharma anticorpos, agente, uso, composto, composição farmacêutica, kits e composição ou uso
KR102781619B1 (ko) 2017-11-15 2025-03-14 이나뜨 파르마 에스.에이. 암의 치료를 위한 인간 CD39 단백질의 ATPase 활성을 결합 및 저해하는 항체
KR20230020023A (ko) 2018-03-14 2023-02-09 서피스 온콜로지, 인크. Cd39에 결합하는 항체 및 이의 용도
TW202012444A (zh) 2018-06-14 2020-04-01 美商貝斯以色列女執事醫療中心有限公司 用於通過外核苷酸酶抑制及抗體介導型靶標細胞攝入來預防或逆轉t 細胞耗竭之組合物及方法
DK3807316T3 (da) 2018-06-18 2024-07-29 Innate Pharma Sammensætninger og fremgangsmåder til behandling af cancer
US20230242660A1 (en) 2019-02-21 2023-08-03 Trishula Therapeutics, Inc. Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies
CA3149494A1 (en) 2019-08-12 2021-02-18 Purinomia Biotech, Inc. Methods and compositions for promoting and potentiating t-cell mediated immune responses through adcc targeting of cd39 expressing cells
JP7727387B2 (ja) 2019-08-27 2025-08-21 エルピサイエンス（スーチョウ）・バイオファーマ，リミテッド 新規の抗ｃｄ３９抗体
KR20220062500A (ko) 2019-09-16 2022-05-17 서피스 온콜로지, 인크. 항-cd39 항체 조성물 및 방법
CN110407941B (zh) 2019-09-25 2020-01-14 上海岸迈生物科技有限公司 Cd39的高亲和力抗体及其用途
CN114651013B (zh) 2019-11-05 2025-03-14 北京加科思新药研发有限公司 对cd39具有特异性的结合分子及其用途
KR20230019414A (ko) 2020-04-03 2023-02-08 트리슐라 테라퓨틱스, 인코포레이티드 항-cd39 항체 및 입양 세포 요법을 포함하는 조합 요법
TW202227506A (zh) 2020-09-10 2022-07-16 美商普瑞諾生物科技公司 藉由靶向NTPDase3增強抗腫瘤免疫反應之方法及組合物
AU2021389989A1 (en) 2020-11-27 2023-06-08 Elpiscience (Suzhou) Biopharma, Ltd. Novel conjugate molecules targeting cd39 and tgfβeta

Also Published As

Publication number Publication date
CN119173535A (zh) 2024-12-20
AR128688A1 (es) 2024-06-05
JP7712496B2 (ja) 2025-07-23
CN119569881B (zh) 2025-11-07
CA3253669A1 (en) 2023-09-07
US11970543B2 (en) 2024-04-30
CL2024002620A1 (es) 2025-01-03
IL315351A (en) 2024-11-01
WO2023165561A1 (en) 2023-09-07
US20250084178A1 (en) 2025-03-13
AU2023227964A1 (en) 2024-09-19
US20240034803A1 (en) 2024-02-01
JP2025508956A (ja) 2025-04-10
EP4486785A1 (en) 2025-01-08
JP2025148452A (ja) 2025-10-07
MX2024010646A (es) 2024-09-19
CN119569881A (zh) 2025-03-07
TW202340243A (zh) 2023-10-16

Similar Documents

Publication Publication Date Title
US11820824B2 (en) Antibodies to TIGIT
EP3471753B1 (en) Anti-pd-l1 and il-2 cytokines
TWI719970B (zh) 針對ｉｃｏｓ之抗體
JP2020180135A (ja) 抗ｐｄ−ｌ１抗体およびその使用
EP3617232A1 (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof
WO2020227071A1 (en) Cd123-binding polypeptides and uses thereof
US11970543B2 (en) Anti-CD39 antibodies and use thereof
BR112018010410A2 (en) method for treating cancer in a subject, composition and methods of increasing the number of nk cells and increasing the number of one or more pd-11 positive cells
US20230054718A1 (en) Anti-galectin-9 antibody and uses thereof
US20250179176A1 (en) Anti-tigit antibodies and uses of the same
WO2023010483A1 (en) Anti-human cxcr5 antibody and uses thereof
WO2023164872A1 (en) Anti-cd39 antibodies and use thereof
US20240158517A1 (en) Anti-human cxcr5 antibody and uses thereof
HK40113788A (zh) 抗cd39抗体及其用途
WO2021091960A1 (en) Methods of treating cancer with anti-pd-1 antibodies
RU2840501C1 (ru) Анти-галектин-9 антитело и его применение
HK40122875A (zh) 抗tigit抗体及其用途
HK40079159A (en) Methods of treating cancer with anti-pd-1 antibodies
HK40014488A (en) Anti-tigit antibodies, anti-pvrig antibodies and combinations thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

E13 Pre-grant limitation requested

Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000